Paper28006993
The structural modification of natural products for novel drug discovery.
Yao H and 4 others. Expert Opin Drug Discov, 2017. Cited by 189 papers, by iCite.
Cite this record
ConductScience Library. The structural modification of natural products for novel drug discovery. Papers, record 28006993. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28006993
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biological Products | Major topic |
| Drug Design | Major topic |
| Drug Discovery | Major topic |
| Drug Stability | |
| Humans | |
| Solubility |
Source PubMed
Cited by85
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 189 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42972149 | From structure prediction to ligand-target recognition: expanding the reach of AlphaFold in natural product research. | Nat Prod Bioprospect | 2026 | https://conductscience.org/library/papers/42972149 | PubMed |
| 42329132 | Modular Framework for 3D Molecular Generation in Computational Chemistry Applications. | J Am Chem Soc | 2026 | https://conductscience.org/library/papers/42329132 | PubMed |
| 42253922 | Progress in Natural Products Target Discovery Technology. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42253922 | PubMed |
| 42249117 | Divergent and precise alkaloid remodelling with a small suite of reactions. | Nat Chem | 2026 | https://conductscience.org/library/papers/42249117 | PubMed |
| 42223756 | Sesamol derivatives bearing a quinazolin moiety: synthesis, antifungal efficacy against tea plant pathogens, and mechanistic insights. | Nat Prod Bioprospect | 2026 | https://conductscience.org/library/papers/42223756 | PubMed |
| 42216452 | A Bio-Based Chiroptical Overcrowded Alkene From Flavanone: Photoreactivity and Theoretical Investigation. | Chemistry | 2026 | https://conductscience.org/library/papers/42216452 | PubMed |
| 42074289 | Targeting the NLRP3 Inflammasome in Atherosclerosis: A Review of Natural Products and Their Molecular Mechanisms. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42074289 | PubMed |
| 41743134 | Anti-GPV activity of Lactobacillus-fermented traditional Chinese medicines. | Front Microbiol | 2026 | https://conductscience.org/library/papers/41743134 | PubMed |
| 41709327 | Investigating the impact and mechanism of Licochalcone B derivative CTG12 on NLRP3 inflammasome. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/41709327 | PubMed |
| 41660905 | Clausenidin from Clausena excavata Burm. causes Apoptosis of Liver Cancer in Mice. | Asian Pac J Cancer Prev | 2026 | https://conductscience.org/library/papers/41660905 | PubMed |
| 41585642 | Creation and Functional Evaluation of a Novel Antioxidant Compound via UV-Induced Structural Transformation of Epicatechin from White Wine Pomace. | ACS Omega | 2026 | https://conductscience.org/library/papers/41585642 | PubMed |
| 41524971 | AI-driven peptide discovery for endometrial cancer: deep generative modeling and molecular simulation in the big data era. | J Comput Aided Mol Des | 2026 | https://conductscience.org/library/papers/41524971 | PubMed |
| 41523743 | Spectrochemical, medicinal, and toxicological studies of moxifloxacin and its novel analogs: a quantum chemistry and drug discovery approach. | RSC Adv | 2026 | https://conductscience.org/library/papers/41523743 | PubMed |
| 41345178 | In-silico investigations of bioactive compounds from ginger against Lassa fever virus nucleoprotein. | Sci Rep | 2025 | https://conductscience.org/library/papers/41345178 | PubMed |
| 41007298 | Therapeutic Potential of Natural Compounds for Brain Ischemia-Reperfusion Injury. | Biology (Basel) | 2025 | https://conductscience.org/library/papers/41007298 | PubMed |
| 40873643 | Emerging Target Discovery Strategies Drive the Decoding of Therapeutic Power of Natural Products and Further Drug Development: A Case Study of Celastrol. | Exploration (Beijing) | 2025 | https://conductscience.org/library/papers/40873643 | PubMed |
| 40808802 | Substituted 1,4-naphthoquinones for potential anticancer therapeutics: In vitro cytotoxic effects and QSAR-guided design of new analogs. | Comput Struct Biotechnol J | 2025 | https://conductscience.org/library/papers/40808802 | PubMed |
| 40510420 | Targeting programmed cell death with natural products: a potential therapeutic strategy for diminished ovarian reserve and fertility preservation. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40510420 | PubMed |
| 40478370 | Bridging chemical space and biological efficacy: advances and challenges in applying generative models in structural modification of natural products. | Nat Prod Bioprospect | 2025 | https://conductscience.org/library/papers/40478370 | PubMed |
| 40141117 | 4(3H)-Quinazolinone: A Natural Scaffold for Drug and Agrochemical Discovery. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40141117 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28006993
GET https://conductscience.org/api/papers/v1/28006993/cited_by?page=2